Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Immunovant (IMVT) Invested Capital (2018 - 2026)

Immunovant filings provide 8 years of Invested Capital readings, the most recent being $986.1 million for Q4 2025.

  • Quarterly Invested Capital rose 179.66% to $986.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $986.1 million through Dec 2025, up 179.66% year-over-year, with the annual reading at $707.4 million for FY2025, 14.52% up from the prior year.
  • Invested Capital hit $986.1 million in Q4 2025 for Immunovant, up from $519.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $986.1 million in Q4 2025 and bottomed at $251.8 million in Q3 2023.
  • Average Invested Capital over 5 years is $494.8 million, with a median of $459.5 million recorded in 2022.
  • The largest annual shift saw Invested Capital skyrocketed 302.51% in 2021 before it tumbled 48.09% in 2024.
  • Immunovant's Invested Capital stood at $505.1 million in 2021, then decreased by 17.91% to $414.7 million in 2022, then soared by 63.82% to $679.3 million in 2023, then tumbled by 48.09% to $352.6 million in 2024, then soared by 179.66% to $986.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Invested Capital are $986.1 million (Q4 2025), $519.7 million (Q3 2025), and $608.5 million (Q2 2025).